MHT + tirzepatide yields 35% more weight loss in women
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Postmenopausal women using menopausal hormone therapy (MHT) while taking tirzepatide lost about 35% more weight than those on tirzepatide alone, per the Mayo Clinic study.
- The retrospective cohort examined 120 adults with overweight or obesity treated with tirzepatide for at least 12 months, comparing outcomes between MHT users and non‑users.
- Researchers note that because the analysis was observational and not randomized, the additional weight loss cannot be definitively attributed to hormone therapy.
- Preclinical evidence suggests estrogen may amplify the appetite‑suppressing effects of GLP‑1‑based drugs, offering a plausible mechanism for the observed synergy.
- Future randomized trials are planned to confirm the findings and assess whether MHT also improves cardiometabolic measures beyond weight loss.
- The Lancet Obstetrics, Gynaecology, & Women’s Health published the study, which was funded by the Mayo Clinic Center for Women’s Health Research.
Why it matters: The 35% greater weight loss observed in postmenopausal women combining MHT with tirzepatide provides a more effective strategy for reducing obesity and cardiometabolic risk, benefiting millions of women facing heightened health challenges after menopause. The findings also highlight the need for randomized trials to establish causality and guide clinical guidelines.
